AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2020

Jan 8, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2020-01-06

Reporting Person: Car Bruce (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-06	Stock option (right to buy)	$48.49	A	47007	Acquired	2030-01-06	Common stock (47007.0)	Direct
2020-01-06	Restricted stock units	$	A	10311	Acquired		Common stock (10311.0)	Direct

Footnotes

F1: This option was granted on January 6, 2020. The shares underlying this option vest as to 25% of the underlying shares on January 6, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F3: The restricted stock units were granted on January 6, 2020. Beginning on January 6, 2021, the shares underlying the restricted stock units will vest in three equal annual installments.